Healthcare Services

Non-invasive Prenatal Testing Market Trends And Growth Outlook Across The 2026–2030 Forecast Period

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Forecasted Market Size Figures For The Non-invasive Prenatal Testing Market In 2026 And 2030?

The non-invasive prenatal testing market has seen a swift increase in its size over recent years. It is anticipated to expand from $6.27 billion in 2025 to $7.21 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.0%. Historically, this expansion has been a result of greater awareness regarding prenatal screening, dependence on invasive diagnostic methods, the rising utilization of assay kits and reagents, the adoption of next-generation sequencing in laboratories, and the demand for early detection of chromosomal abnormalities.

The non-invasive prenatal testing market is projected to experience swift expansion over the coming years. This market is anticipated to reach a valuation of $12.37 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.4%. Key factors driving this growth during the projected period include the global increase in the use of non-invasive prenatal testing, greater investment in sophisticated sequencing technologies, the expansion of networks of hospitals and diagnostic laboratories, a rising need for early genetic screening, and the progressive incorporation of AI and data analytics into prenatal diagnostics. Significant trends identified for the forecast timeframe encompass the increasing embrace of AI-driven genetic analysis, the expanded application of NGS and PCR systems in prenatal testing, the growing deployment of cloud-based data management solutions in diagnostics, the wider adoption of high-throughput screening technologies, and the evolving integration of personalized prenatal risk assessment methods.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2492&type=smp

Which Strategic Drivers Are Supporting The Non-invasive Prenatal Testing Market Development?

The non-invasive prenatal testing market is expected to grow, driven by the increasing age of mothers. This rise in maternal age is influenced by factors such as the pursuit of education, career development, financial security, individual preference, later marriages, improved birth control methods, and evolving societal trends, enabling women to make more deliberate decisions about family planning. As women postpone childbirth, the likelihood of chromosomal abnormalities increases, leading more expectant mothers to choose NIPT to evaluate the health of their pregnancies. For instance, in March 2025, data from the Centers for Disease Control and Prevention, a US-based government agency, indicated that in 2023, the average age of mothers at their first birth reached 27.5 years, an increase from 27.4 in 2022, establishing another record high for the nation. Therefore, the upward trend in maternal age will continue to boost the growth of the non-invasive prenatal testing market.

How Is The Non-invasive Prenatal Testing Market Distributed Across Key Segments?

The non-invasive prenatal testing market covered in this report is segmented –

1) By Type: Consumables, Instruments

2) By Application: Trisomy, Microdeletion, Genetics, Rh factor

3) By End User: Hospital, Diagnostic Labs

Subsegments:

1) By Consumables: Assay Kits, Reagents, Disposables

2) By Instruments: Next-Generation Sequencers (NGS), Polymerase Chain Reaction (PCR) Systems, Ultrasound Devices

What Trends Are Affecting The Growth Of The Non-invasive Prenatal Testing Market?

Leading companies within the non-insulin therapies for diabetes market are prioritizing the development of advanced solutions, such as non-insulin GLP-1 receptor agonists. This focus aims to expand available treatment options, improve glycemic control, and strengthen their competitive foothold in the diabetes and obesity care sector. The introduction of non-insulin GLP-1 receptor agonists signifies the availability of therapies that target GLP-1 receptors to aid in blood glucose regulation and weight reduction without relying on insulin. For example, in March 2025, Eli Lilly and Company, a US-based pharmaceutical company specializing in diabetes and metabolic therapies, introduced Mounjaro (tirzepatide) in India, following its approval from the Central Drugs Standard Control Organisation. Mounjaro, engineered as a dual GIP and GLP-1 receptor agonist, addresses critical challenges in type 2 diabetes and obesity management through once-weekly subcutaneous administration. It works by enhancing glycemic control, reducing appetite, slowing gastric emptying, and supporting significant weight reduction, with initial dosing options of 2.5 mg and 5 mg to improve patient adherence and long-term outcomes.

Which Companies Are Engaged In The Non-invasive Prenatal Testing Market Environment?

Major companies operating in the non-invasive prenatal testing market are F. Hoffmann-La Roche AG, Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., PerkinElmer Inc., Quest Diagnostics Inc., Agilent Technologies Inc., BGI Diagnosis Co Ltd., Berry Genomics Co, LifeCodexx AG, Myriad Genetics Inc., NIPD Genetics Co Ltd., Sequenom Inc., Annoroad Gene Technology Co Ltd., Centogene AG, Counsyl Inc., EUROFINS Genoma Group, Eurofins Scientific SE, Next Biosciences, Premaitha Health Plc, Ariosa Diagnostics Inc., Yourgene Health PLC, GE Healthcare Technologies Inc., Koninklijke Philips NV, Thermo Fisher Scientific Inc., Pacific Biosciences of California Inc., QIAGEN NV, MedGenome Labs Ltd., Progenity Inc., Beijing Genomics Institute

Access The Complete Non-invasive Prenatal Testing Market Report:

https://www.thebusinessresearchcompany.com/report/non-invasive-prenatal-testing-global-market-report

Which Area Represents The Largest Portion Of The Non-invasive Prenatal Testing Market?

North America was the largest region in the non-invasive prenatal testing market in 2025. Western Europe was the second largest region in the non-invasive prenatal testing market. The regions covered in the non-invasive prenatal testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Non-invasive Prenatal Testing Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=2492&type=smp

Browse Through More Reports Similar to the Global Non-invasive Prenatal Testing Market 2026, By The Business Research Company

Non Injectable Insulin Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

Oem Insulation Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/oem-insulation-global-market-report

Antidiabetics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795